Anti-RAGE Agent Targeting V Domain for Cardiac Cachexia
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cardiac dysfunction associated with RAGE and cachexia are inadequate, and there is a need for methods to identify therapeutic agents that can inhibit cachexia-induced signaling in cells by targeting specific sites on the RAGE polypeptide or its ligands.
Innovation Solution
Development of pharmaceutical compositions containing agents that specifically bind to RAGE polypeptides at specific amino acid residues, inhibiting the binding of RAGE ligands, and using anti-RAGE antibodies or small molecule compounds to disrupt cachectogenic signaling, along with methods to identify candidate compounds using three-dimensional structures and high-throughput screening.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for cardiac dysfunction, then general cardiac symptoms are addressed, but cachexia-induced signaling and RAGE-mediated pathways are not effectively inhibited
Solution Approach 1:
The patent segments the RAGE polypeptide into specific functional domains, particularly focusing on the V domain (amino acids 23-220) and identifying specific epitopes within this region. By targeting specific segments of the RAGE polypeptide rather than using general cardiac treatments, the invention achieves selective inhibition of cachexia-induced signaling while maintaining treatment reliability.
Solution Approach 2:
The patent applies local quality by developing agents that bind to specific local regions of the RAGE polypeptide, particularly the V domain containing amino acids 23-220. This localized targeting ensures that only specific RAGE-mediated pathways involved in cachexia are inhibited, while other physiological functions of RAGE may remain unaffected, thereby improving both reliability and adaptability.
2Reliability
If agents bind to multiple sites on RAGE polypeptide, then broader RAGE activity is inhibited, but specificity for cachectogenic signaling may be reduced
Solution Approach 1:
The patent divides the RAGE polypeptide binding sites into distinct segments, with primary focus on the V domain (amino acids 23-220) and specifically on epitopes containing amino acids such as 25, 54, 59, 61, 91, 92, 94, 96, 98, 114, 116, 150, 151, 152, 154, 175, 177, 178, 179, 186, 213, 214, and 216. This segmentation allows for precise targeting of cachectogenic signaling while maintaining the ability to inhibit broader RAGE activity when needed.
Solution Approach 2:
The patent employs local quality by designing agents with high affinity for specific local epitopes within the RAGE V domain. This enables precise measurement and control of binding specificity, allowing researchers to select agents that target either specific cachectogenic pathways or broader RAGE functions depending on the therapeutic needs.
3Productivity
If high-throughput screening methods are used to identify therapeutic agents, then compound identification speed increases, but resource requirements and system complexity increase
Solution Approach 1:
The patent segments the screening process into manageable components: (1) expressing RAGE polypeptide or its V domain in host cells, (2) exposing cells to test compound libraries, (3) measuring changes in cachexia-related markers, and (4) identifying active compounds. This segmentation enables high-throughput screening to be performed in a systematic, scalable manner that balances productivity with manageable complexity.
Solution Approach 2:
The patent uses host cells expressing RAGE polypeptide as an intermediary system between the test compounds and the cachexia signaling pathway. This cellular intermediary simplifies the screening process by providing a direct readout of compound activity on RAGE-mediated cachexia signaling, thereby increasing identification speed while keeping the system complexity manageable through standardized cell-based assays.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach effectively inhibits or reverses cardiac dysfunction by targeting RAGE-mediated signaling, preventing loss of myosin heavy chain in cardiomyocytes and treating cachexia-associated cardiac issues, offering a novel route for treating cardiac dysfunction and identifying therapeutic agents.
Implementation Method 1
an agent that specifically binds to a RAGE polypeptide at a site containing one or more of the amino acid residues 25, 54, 59, 61, 91, 92, 94, 96, 98, 114, 116, 150, 151, 152, 154, 175, 177, 178, 179, 186, 213, 214, and 216 of the RAGE polypeptide
Data Source
AI summary
The invention provides compositions and methods for treating cardiac dysfunction, particularly cachexia-associated or RAGE-associated cardiac dysfunction, using an anti-RAGE agent. The invention also provides compositions and methods for identifying therapeutic agents useful for disrupting (slowing, reducing, reversing, or preventing). The methods comprise designing or identifying agents that bind to functional sites identified on the RAGE polypeptide, wherein binding of agents to the functional site(s) inhibit RAGE-mediated cachetogenic signaling.